Atea Pharmaceuticals, Inc. (AVIR)
After hours:
| Previous Close | 3.3000 |
| Open | 3.3700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.3700 - 3.5000 |
| 52 Week Range | 2.8800 - 4.6000 |
| Volume | |
| Avg. Volume | 191,546 |
| Market Cap | 292.242M |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0700 |
| Earnings Date | Feb 26, 2025 - Mar 03, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.89 |
GlobeNewswireAtea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 7th Annual Evercore He
Simply Wall St.Promising US Penny Stocks To Watch In November 2024
As U.S. stock futures rise and major indexes approach record highs, investors are increasingly looking for opportunities in various sectors of the market. Penny stocks, while often seen as a relic from past trading eras, remain relevant due to their potential for growth when supported by strong financials. These smaller or newer companies can offer a unique blend of affordability and growth potential, making them an intriguing option for those seeking hidden value in the market.
